VCNX - Vaccinex, Inc.
| Previous Close | 5.38 |
| Open | 5.50 |
| Bid | 5.00 x 900 |
| Ask | 5.40 x 800 |
| Day's Range | 5.50 - 5.50 |
| 52 Week Range | 3.32 - 8.49 |
| Volume | 239 |
| Avg. Volume | 5,127 |
| Market Cap | 92.429M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.01 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.33 |
- GlobeNewswire
Vaccinex Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced financial results for the third quarter ended September 30, 2019 and provided a corporate update.
- GlobeNewswire
Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that updated interim data of the Phase 1b/2 study of pepinemab in combination with anti-PD-L1 checkpoint inhibitor, BAVENCIO® (avelumab), in non-small cell lung cancer (NSCLC) is being reported during a poster presentation on Saturday, November 9 at the 34th Annual Meeting of The Society for Immunotherapy of Cancer (“SITC”). Below is a summary of updated interim data from the poster presentation.
- GlobeNewswire
Orgenesis Appoints Bala S. Manian to its Scientific Advisory Board
GERMANTOWN, Md., Oct. 31, 2019 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO.
- GlobeNewswire
Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conference in Paris, France
ROCHESTER, N.Y., Sept. 27, 2019 -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and.
- GlobeNewswire
Vaccinex to Present at the Ladenburg Thalmann 2019 Healthcare Conference
ROCHESTER, N.Y., Sept. 24, 2019 -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and.
- GlobeNewswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Vaccinex, Inc.- VCNX
NEW YORK, Sept. 06, 2019 -- Levi & Korsinsky announces it has commenced an investigation of Vaccinex, Inc. (NASDAQCM: VCNX) concerning possible breaches of fiduciary duty..
- Zacks
Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study
Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.
- GlobeNewswire
Vaccinex Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced financial results for the second quarter ended June 30, 2019 and provided a corporate update.
- GlobeNewswire
Vaccinex Announces Full Enrollment Achieved in Ongoing CLASSICAL-Lung Phase 1b/2 Trial of Pepinemab in Combination with BAVENCIO® (avelumab) in Advanced Non-Small Cell Lung Cancer
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that full enrollment has been achieved in the ongoing CLASSICAL-Lung Phase 1b/2 clinical trial evaluating the company’s lead clinical candidate, pepinemab (VX15/2503), in combination with anti-PD-L1 checkpoint inhibitor, BAVENCIO® (avelumab), for the treatment of advanced non-small cell lung cancer (NSCLC). The clinical trial is being conducted in collaboration with Merck KGaA, Darmstadt, Germany and Pfizer.
- GlobeNewswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Vaccinex, Inc.- VCNX
NEW YORK, Aug. 12, 2019 -- Levi & Korsinsky announces it has commenced an investigation of Vaccinex, Inc. (NASDAQCM: VCNX) concerning possible breaches of fiduciary duty..
- GuruFocus.com
Insiders Roundup: Bezos Sells Amazon
Largest insider trades of the week Continue reading...
- GuruFocus.com
Vaccinex Inc (VCNX) President and CEO Maurice Zauderer Bought $750,002 of Shares
President and CEO of Vaccinex Inc (30-Year Financial, Insider Trades) Maurice Zauderer (insider trades) bought 183,824 shares of VCNX on 07/30/2019 at an average price of $4.08 a share. Continue reading...
- GlobeNewswire
Vaccinex Announces $13.8 Million Private Placement
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that the company entered into a stock purchase agreement prior to the market close on July 26, 2019 with a syndicate of new and existing investors for a private placement of 3,382,332 shares of common stock at a purchase price of $4.08 per share for aggregate gross proceeds of approximately $13.8 million. No warrants, derivatives, or financial covenants are associated with the purchase agreement. Participants in the private placement include lead investors FCMI Parent Co. and Vaccinex (Rochester), L.L.C., both existing significant shareholders, as well as an additional major ( 5%) new shareholder.
- GlobeNewswire
Vaccinex Presents Updated Interim Results from a Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at the 2019 ASCO Annual Meeting
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that updated interim results of the Phase 1b/2 study of pepinemab in combination with avelumab in non-small cell lung cancer (NSCLC) subjects were reported during a poster session on Saturday, June 1 at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Michael Shafique, M.D., Assistant Professor of Thoracic Oncology at the H. Lee Moffitt Cancer Center and Research Institute and first author of the presentation, presented “Interim results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC” during the Developmental Immunotherapy and Tumor Immunobiology poster session.
- GlobeNewswire
Vaccinex Announces Poster Presentations at the 2019 ASCO Annual Meeting
ROCHESTER, N.Y., May 15, 2019 -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and.
- GlobeNewswire
Vaccinex Reports First Quarter 2019 Financial Results and Provides Corporate Update
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced financial results for the first quarter ended March 31, 2019, and provided a corporate update. Presented interim results from the dose escalation phase of the ongoing CLASSICAL-Lung Phase 1b/2 study at the American Association for Cancer Research (AACR).
- GlobeNewswire
Vaccinex, Inc. Summary of Key Data Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)
ROCHESTER, N.Y., April 09, 2019 -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and.
- GlobeNewswire
Vaccinex, Inc. to Provide Clinical Data on Posters Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)
ROCHESTER, N.Y., April 01, 2019 -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and.
- GlobeNewswire
Vaccinex, Inc. to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference on March 19, 2019
ROCHESTER, N.Y., March 13, 2019 -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and.
- GlobeNewswire
Vaccinex Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announced financial results for the fourth quarter and year-ended December 31, 2018, and provided a corporate update. Announced completion of enrollment in cohort B of its ongoing Phase 2, multi-center, randomized, double-blind, placebo-controlled SIGNAL study.
- GlobeNewswire
Vaccinex, Inc. to Present Data on Its Anti-SEMA4D Compound at the American Association for Cancer Research Annual Meeting 2019
ROCHESTER, N.Y., March 06, 2019 -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to.
- GlobeNewswire
Vaccinex, Inc. Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503 (Pepinemab) in Huntington’s Disease (the “SIGNAL Trial”) at Cambridge Healthtech Institute’s 18th Annual PepTalk
ROCHESTER, N.Y., Jan. 17, 2019 -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to.
- GlobeNewswire
Vaccinex, Inc. Announces Completion of Enrollment for Its “SIGNAL” Huntington’s Disease Trial
ROCHESTER, N.Y., Jan. 16, 2019 -- Vaccinex, Inc. (Nasdaq: VCNX) announced today that it has completed subject enrollment for the SIGNAL trial. SIGNAL is a Phase 2,.
- Simply Wall St.
Do Insiders Own Lots Of Shares In Vaccinex, Inc. (NASDAQ:VCNX)?
A look at the shareholders of Vaccinex, Inc. (NASDAQ:VCNX) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning Read More...
- GlobeNewswire
Preclinical Data on Vaccinex, Inc. Anti-SEMA4D Monoclonal Antibody in Combination with Checkpoint Inhibitors Published in Cancer Immunology Research
ROCHESTER, N.Y., Dec. 12, 2018 -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to.
